Literature DB >> 9744474

Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population.

M Horowitz1, M Pasmanik-Chor, Z Borochowitz, T Falik-Zaccai, K Heldmann, R Carmi, R Parvari, H Beit-Or, B Goldman, L Peleg, E Levy-Lahad, P Renbaum, S Legum, R Shomrat, H Yeger, D Benbenisti, R Navon, V Dror, M Shohat, N Magal, N Navot, N Eyal.   

Abstract

Gaucher disease is the most prevalent inherited disease among Ashkenazi Jews. It is very heterogeneous due to a large number of mutations within the glucocerebrosidase gene, whose impaired activity is the cause for this disease. Aiming at determining Gaucher carrier frequency among the Ashkenazi Jewish population in Israel, 1,208 individuals were molecularly diagnosed for six mutations known to occur among Ashkenazi Jewish Gaucher patients, using the newly developed Pronto Gaucher kit. The following mutations were tested: N370S, 84GG, IVS2+1, D409H, L444P, and V394L. Molecular testing of these mutations also allows identification of the recTL allele. The results indicated that Gaucher carrier frequency is 1:17 within the tested population. The prevalence of N370S carriers is 1:17.5. This implies that approximately 1:1225 Ashkenazi Jews will be homozygous for the N370S mutation. Actually, in our study of 1,208 individuals one was found to be homozygous for the N370S mutation. The actual number of known Ashkenazi Jewish Gaucher patients with this genotype is much lower than that expected according to the frequency of the N370S mutation, suggesting a low penetrance of this mutation. Results of loading experiments in cells homozygous for the N370S mutation, as well as cells homozygous for the L444P and the D409H mutations, exemplified this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744474     DOI: 10.1002/(SICI)1098-1004(1998)12:4<240::AID-HUMU4>3.0.CO;2-J

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  29 in total

Review 1.  Revised recommendations for the management of Gaucher disease in children.

Authors:  Paige Kaplan; Hagit Baris; Linda De Meirleir; Maja Di Rocco; Amal El-Beshlawy; Martina Huemer; Ana Maria Martins; Ioana Nascu; Marianne Rohrbach; Lynne Steinbach; Ian J Cohen
Journal:  Eur J Pediatr       Date:  2012-07-08       Impact factor: 3.183

2.  The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms.

Authors:  Richard A Steet; Stephen Chung; Brandon Wustman; Allan Powe; Hung Do; Stuart A Kornfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-31       Impact factor: 11.205

3.  Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy.

Authors:  Reena V Kartha; James Joers; Marcia R Terluk; Abigail Travis; Kyle Rudser; Paul J Tuite; Neal J Weinreb; Jeanine R Jarnes; James C Cloyd; Gülin Öz
Journal:  J Inherit Metab Dis       Date:  2019-12-17       Impact factor: 4.982

4.  Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases.

Authors:  Stuart A Scott; Lisa Edelmann; Liu Liu; Minjie Luo; Robert J Desnick; Ruth Kornreich
Journal:  Hum Mutat       Date:  2010-11       Impact factor: 4.878

5.  Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes.

Authors:  Vladimir Vacic; Laurie J Ozelius; Lorraine N Clark; Anat Bar-Shira; Mali Gana-Weisz; Tanya Gurevich; Alexander Gusev; Merav Kedmi; Eimear E Kenny; Xinmin Liu; Helen Mejia-Santana; Anat Mirelman; Deborah Raymond; Rachel Saunders-Pullman; Robert J Desnick; Gil Atzmon; Edward R Burns; Harry Ostrer; Hakon Hakonarson; Aviv Bergman; Nir Barzilai; Ariel Darvasi; Inga Peter; Saurav Guha; Todd Lencz; Nir Giladi; Karen Marder; Itsik Pe'er; Susan B Bressman; Avi Orr-Urtreger
Journal:  Hum Mol Genet       Date:  2014-05-19       Impact factor: 6.150

6.  Intracellular degradation of fluorescent glycolipids by lysosomal enzymes and their activators.

Authors:  L Madar-Shapiro; M Pasmanik-Chor; T Dinur; A Dagan; S Gatt; M Horowitz
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

7.  Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease.

Authors:  M J Barrett; J Hagenah; V Dhawan; S Peng; K Stanley; D Raymond; A Deik; S J Gross; N Schreiber-Agus; A Mirelman; K Marder; L J Ozelius; D Eidelberg; S B Bressman; R Saunders-Pullman
Journal:  Parkinsonism Relat Disord       Date:  2012-10-10       Impact factor: 4.891

Review 8.  Modelling human disease with pluripotent stem cells.

Authors:  Richard Siller; Sebastian Greenhough; In-Hyun Park; Gareth J Sullivan
Journal:  Curr Gene Ther       Date:  2013-04       Impact factor: 4.391

9.  Pronto ThromboRisk--a novel primer-extension ELISA based assay for the detection of mutations associated with increased risk for thrombophilia.

Authors:  Noga Carmi; Dana Cohen; Eti Zvang; Elizabeth Naparstek; Varda Deutsch
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

10.  False-positive results using a Gaucher diagnostic kit--RecTL and N370S.

Authors:  Jae Hyuk Choi; Arash Velayati; Barbara K Stubblefield; Avi Orr-Urtreger; Ziv Gan-Or; Nahid Tayebi; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2010-01-04       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.